Loading clinical trials...
Loading clinical trials...
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Conditions
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Placebo
+1 more
Locations
39
United States
Penrose Hospital
Colorado Springs, Colorado, United States
St. Francis Health Services
Colorado Springs, Colorado, United States
St. Anthony Hospital
Lakewood, Colorado, United States
Saint Anthony North Health Campus
Westminster, Colorado, United States
Washington VA Medical Center
Washington D.C., District of Columbia, United States
Redmond Regional Medical Center
Rome, Georgia, United States
Start Date
October 8, 2020
Primary Completion Date
May 21, 2021
Completion Date
May 21, 2021
Last Updated
April 4, 2022
NCT06631287
NCT05101213
NCT06850350
NCT04565665
NCT06871293
NCT07298005
Lead Sponsor
University of Minnesota
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions